Quick Answer
CytomX Therapeutics, Inc. reported Revenue (ASC 606) of $76.20 million for fiscal year 2025.
CytomX Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $76.20M | -44.8% |
| 2024 | $138.10M | +36.4% |
| 2023 | $101.21M | +90.4% |
| 2022 | $53.16M | +42.5% |
| 2021 | $37.31M | -62.8% |
| 2020 | $100.36M | +74.6% |
| 2019 | $57.49M | -3.4% |
| 2018 | $59.50M | -16.9% |
| 2017 | $71.62M | +457.6% |
| 2016 | $12.85M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.96M | -82.2% | -68.0% |
| June 30, 2025 | $18.66M | -25.7% | -63.4% |
| March 31, 2025 | $50.92M | +22.8% | +52.3% |
| September 30, 2024 | $33.43M | +26.7% | +33.1% |
| June 30, 2024 | $25.11M | +1.6% | -39.4% |
| March 31, 2024 | $41.46M | +76.4% | +57.2% |
| September 30, 2023 | $26.38M | +136.7% | +6.7% |
| June 30, 2023 | $24.72M | +92.4% | +5.2% |
- CytomX Therapeutics, Inc. showed a decrease of -44.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, CytomX Therapeutics, Inc.’s revenue (asc 606) has grown by 493.2% (from $12.85 million to $76.20 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: